France assesses population's hepatitis C status:
This article was originally published in Clinica
Executive Summary
A pilot screening project has been set up in general practitioner practices in four areas in France, to assess levels of hepatitis C infection in the population. The project's main objectives are to evaluate the cost-effectiveness of different screening strategies and to identify the risk factors so that carriers may be more easily identified before establishing a general screening plan. According to Lettre CNAM, the national insurer's newsletter, it is estimated that 1% of the French population are carriers of hepatitis C and only 20% of these are aware of their status.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.